Merck and Sanofi recently announced that their six-in-one combination pediatric vaccine is now available throughout the US.
Vaxelis is the first and only hexavalent combination vaccine available...
Moderna and Aldevron recently expanded their partnership to support Moderna’s mRNA COVID-19 vaccine and clinical development therapeutic pipeline.
Aldevron is a provider of plasmid DNA,...
AstraZeneca’s COVID-19 vaccine, Vaxzevria, was recently granted emergency use in Japan for active immunization of individuals 18 years of age and older.
The Japanese Ministry of Health,...
Moderna recently announced that the Phase 2/3 study of its COVID-19 vaccine in adolescents met its primary immunogenicity endpoint, successfully bridging immune response to the adult...
FDA recently approved Janssen’s Rybrevant as the first targeted therapy for patients with subset of non-small cell lung cancer.
The agency approved the therapy based on a study of 81...
Medicago’s Coronavirus-Like Particle COVID-19 Vaccine Candidate (CoVLP) elicited significant humoral immune response across all age groups when administered in combination with GSK’s...
Abbott recently announced that it received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, for individuals with severe aortic stenosis in...
A multisite test-negative design case-control CDC study recently found that the mRNA COVID-19 vaccines from Pfizer and Moderna are highly effective against symptomatic coronavirus.
The study analyzed...
Eli Lilly and Company and MiNA Therapeutics recently entered into a global research collaboration that will leverage small activating RNA (saRNA) research technology for drug discovery.
MiNA...
Eli Lilly and Company recently signed strategic international agreements with four companies to advance connected solutions and streamline diabetes care management for individuals living with the...
FDA recently expanded the emergency use authorization for the Pfizer COVID-19 vaccine to include adolescents 12 through 15 years of age.
The agency amended the original emergency use authorization...
JAMA Network Open study found that change in brand-name medication prices for most commercially insured patients correlated with changes in out-of-pocket costs.
In the study, nearly 53.7 percent of...
FDA recently approved AstraZeneca’s Farxiga oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular, death, and hospitalization for heart failure in adults with...
A Kaiser Family Foundation analysis recently found that a small number drugs accounted for a disproportionate share of Medicare prescription drug spending in 2019.
Researchers measured the share...
A JAMA Network Open study found that COVID-19 treatments hydroxychloroquine and lopinavir-ritonavir failed to show any significant benefit in hospitalized patients.
The study analyzed metrics such...
New COVID-19 drug therapies along with better clinical management of patients with SARS-CoV-2 infection may have contributed to reductions in in-hospital COVID-19 mortality rates, according to a recent...
FDA recently revoked the emergency use authorization that allowed for Eli Lilly & Company’s monoclonal COVID-19 antibody, bamlanivimab, to be used for coronavirus treatment in adults and...
FDA recently approved Opdivo, making it the first immunotherapy for initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal...
Eli Lilly and Company recently requested that FDA revoke the emergency use authorization for its COVID-19 antibody treatment.
The FDA’s authorization has allowed providers to use 700 milligrams...
AstraZeneca recently announced that China approved its prescription drug, Tagrisso, for the treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung...
